Research Notes
Group revenue at Farmacosmo rose in the second quarter of 2026 to about 9.9 million euros, 19% above the 8.4 million euros of the first quarter, after a weaker first quarter; first-half revenue of 18.4 million euros still came in 10% below the 20.4 million euros of the same period of 2025, so the rebound is not yet confirmed, and repeat-purchase revenue on farmacosmo.it is the indicator that would confirm it.
The main farmacosmo.it portal carried 63% of the group's total revenue, and the share of recurring revenue generated by customers who made more than one purchase on farmacosmo.it rose from 83% in 2024 to over 85% in 2025.
Farmacosmo shut its B2B channel permanently during the year ended 31 December 2025, the period for which its board approved consolidated and draft statutory accounts, finishing a retreat from business-to-business sales that had reduced that segment to 7% of group revenue after a 73% fall versus 2024, while bolstering its retail component.
The B2B share stood at 56% when Farmacosmo listed, and its board approved the consolidated and draft statutory accounts for the year ended 31 December 2024.
Farmacosmo.it lets consumers satisfy pharmacy, perfumery, herbalist and pet-product shopping in a single online basket instead of visiting each of those shops separately, with over-the-counter medicines, organic products and baby products available in the same cart. Orders from EUR 69 ship free across Italy and the European Union, and pickup is available at GLS and Bartolini FermoPoint points.
Farmacosmo.it's business model rests on three areas: logistics, intelligence and node, with logistics handling up to 12,000 orders daily. The average cart value for Farmacosmo.it is 102 euros.
Restructuring write-downs could keep impairing Farmacosmo's equity because 2.9 million euros of the 5.6 million euros in amortisation and write-downs that drove the year's 4.6 million euro loss tie to the B2B business closure, while adjusted EBITDA of 2.3 million euros, equal to 4.7% of the value of production, and an 81% improvement in net financial position from negative 3.9 million euros at the end of 2024 to negative 2.2 million euros show the operating business still earns a positive return.
Group revenue in the first half of 2026 was 18.4 million euros, down 10% from the 20.4 million euros recorded in the same period of 2025, as the group prioritised first-level margin, which rose a further 3%, at the expense of overall revenue volume.
